News about "Sanofi"

Sanofi, Regeneron Expand Alliance to Develop Four Long-Acting Antibodies

Sanofi and Regeneron expands their antibody collaboration to develop and commercialise four next-generation long-acting antibodies for immune-mediated diseases.

Sanofi | 03/10/2026 | By News Bureau |  120

Sanofi and Cheplapharm Announce Strategic Partnership for 20 Mature Medicines and Three Sites

Sanofi and Cheplapharm plan to transfer 20 mature medicines and three manufacturing sites to Cheplapharm, with Sanofi set to receive a 26.4 percent equity stake.

Sanofi | 16/09/2026 | By News Bureau |  108

European Commission Expands Sanofi's MenQuadfi Approval to Include Infants from Six Weeks of Age

The European Commission has approved an expanded indication for Sanofi's MenQuadfi vaccine, allowing immunisation of infants from six weeks of age against invasive meningococcal disease caused by serogroups A, C, W and Y.

Sanofi | 05/08/2026 | By News Bureau |  119

EU Approves Sanofi's MenQuadfi for Invasive Meningococcal Disease

Sanofi's MenQuadfi has received European Union (EU) approval for infants from 6 weeks of age, expanding protection against invasive meningococcal disease.

Sanofi | 04/08/2026 | By News Bureau |  156

Sanofi to not Submit Amlitelimab in Atopic Dermatitis for Global Regulatory Reviews

Sanofi will not seek global regulatory approval for amlitelimab in Atopic Dermatitis (AD) after efficacy and safety data did not support further development.

Sanofi | 27/07/2026 | By News Bureau |  193

Sanofi Reshapes Executive Committee to Drive Next Phase of Growth

Sanofi has revamped its Executive Committee with a focused leadership team to drive strategic growth, accelerate innovation, and prepare for its next chapter.

Sanofi | 23/07/2026 | By News Bureau |  246

Sanofi's Nexviazyme Meets Primary Goal in Phase 3 Study for Infantile-Onset Pompe Disease

Sanofi's Phase 3 Baby-COMET study showed Nexviazyme improved ventilator-free survival in infants with infantile-onset Pompe disease, supporting plans for a US regulatory filing to expand the therapy's approved indication.

Sanofi | 01/07/2026 | By News Bureau |  190

EU Approves Sanofi's Cenrifki (Tolebrutinib) for Multiple Sclerosis

The European Commission (EC) has approved Sanofi’s Cenrifki (tolebrutinib) as the first disability-targeting treatment for adults with Secondary Progressive Multiple Sclerosis (SPMS) without relapses.

Sanofi | 25/06/2026 | By News Bureau |  272

Japan Approves Sanofi's Wayrilz for Immune Thrombocytopenia

Sanofi’s Wayrilz has been approved in Japan for the treatment of immune thrombocytopenia (ITP). The BTK inhibitor works through multi-immune modulation to address the underlying causes of the disease.

Sanofi | 24/06/2026 | By News Bureau |  110

Sanofi Names Paulo Fontoura to Lead Global R&D Operations

Sanofi has appointed Paulo Fontoura as Global Head of Research and Development (R&D). Based in Paris, he will join the Executive Committee and report directly to CEO Belén Garijo.

Sanofi | 23/06/2026 | By News Bureau |  251